Compare Neurocrine Biosciences Inc (NBIX) vs Invesco S&P 500 High Div Low Volatility ETF (SPHD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Invesco S&P 500 High Div Low Volatility ETF — how do they compare? Neurocrine Biosciences Inc trades at $158.32 (market cap $16.46B), while Invesco S&P 500 High Div Low Volatility ETF trades at $52.22. The key difference: Invesco S&P 500 High Div Low Volatility ETF is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| NBIX | SPHD | |
|---|---|---|
Market Cap | $16.46B | — |
Sector | Health | — |
52-Week High | $185.50 | $53.55 |
52-Week Low | $123.10 | $46.96 |
Enterprise Value | $16.48B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $158.89, down 3.66% in the past 24 hours, reflecting near-term bearish technical signals. The stock shows strong fundamentals with Q2 2026 revenue growth of 39% year-over-year to $959 million and a net income margin of 20.91%. Recent news highlights include positive clinical data for INGREZZA and the initiation of a Phase 1 study for a GLP-1/GIP/glucagon receptor triple agonist, though safety concerns were raised for Vykat XR in Prader-Willi Syndrome.
The outlook remains positive given robust earnings beats, raised 2026 sales guidance, and a consensus price target of $208.82 implying significant upside. Risks include clinical trial setbacks, competitive pressures, and regulatory scrutiny. Analyst sentiment is strongly bullish with 86% buy ratings, supporting a growth-oriented investment case amid near-term volatility.
SPHD trades at $52.26, down 0.29% today, with a bullish technical signal supported by moving averages. The ETF focuses on high-dividend, low-volatility S&P 500 stocks, offering monthly income. Recent news highlights investor interest in dividend and value strategies amid market volatility, with articles from Zacks and 24/7 Wall Street in August 2026 emphasizing its role in retirement portfolios.
The outlook for SPHD is stable, appealing for income-focused investors seeking lower volatility. Key opportunities include consistent dividends and defensive positioning, while risks involve interest rate sensitivity and potential underperformance in strong bull markets. Analyst sentiment is generally positive for its strategy in current conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Invesco S&P 500 High Div Low Volatility ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the “index Provider”) compiles, maintains and calculates the underlying index, which is designed to measure the performance of 50 least volatile high yielding constituents of the S&P 500 ® Index in the past year.
Read more on SPHD →
